Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Cancer Chemother Pharmacol. 2018 Dec 8;83(3):473–482. doi: 10.1007/s00280-018-3749-7

Figure 1.

Figure 1.

Patient dasatinib concentrations over time after 100 mg (○) or 200 mg (Δ) of dasatinib PO, in plasma (2–8 h), 8–9 h normal tissue (N) or tumor (T), and the tumor/normal tissue ratio (T/N, secondary Y-axis).